Clostridioides difficile Infection Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Clostridioides difficile Infection remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 77 matched trial records and 165 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07649096 | FZ-002 | Phase 1; Not yet recruiting | National Institute of Allergy & Infectious Diseases | Geography not listed | Occurrence of serious adverse events (SAEs) (Through Day 208); Occurrence of solicited adverse events (AEs) (Through Day 35) | 2028-08-22 |
| NCT07613645 | Intervention not normalized | Not Applicable; Recruiting | University of Michigan | United States | Change from baseline to week 2 in alpha-diversity of fecal microbiome by 16S rRNA sequencing (Baseline, 2 weeks (post feeding period)) | 2027-12-01 |
| ChiCTR2600125056 | Intervention not normalized | Not Applicable; Not yet recruiting | The First Affiliated Hospital of Xiamen University | China | Adverse Event (Treatment Period，Follow-up Period) | 2029-03-01 |
| ChiCTR2600124621 | Intervention not normalized | Not Applicable; Not yet recruiting | Fuzhou University | China | Safety (within 3 days after treatment initiation, and at weeks 1, 2, 3, 4, and 8.); Incidence of adverse events (AEs) and serious adverse events (SAEs) (within 3 days after treatment initiation, and at weeks 1, 2, 3, 4, and 8.) | 2027-08-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study (Phase 2): the indexed record reports CCR = 100.0 %; CCR = 93.0 %; CCR = 93.0 %.
- A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection (Phase 3): the indexed record reports Number of Participants With RBX2660-related Treatment-emergent Adverse Events (TEAEs) After RBX2660 Treatment Delivered by Colonoscopy Through 8 Weeks, or Treatment Failure = 18 Participants; -; -.
- Randomized Double Blind Controlled Trial for the Treatment of Nucleic Acid Amplification Test (NAAT)+/Toxin Enzyme Immunoassay (EIA)- Clostridium Difficile in the Hematology Oncology Population (Phase 2): the indexed record reports -; Mean - first sample(Mean) = 62102500.00 CFUs (Standard Deviation, 79994345.79); -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including FZ-002 (Phase 1; SSTR4). Company & Deal Intelligence records identify sponsor context for National Institute of Allergy & Infectious Diseases, University of Michigan, The First Affiliated Hospital of Xiamen University, Fuzhou University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Clostridioides difficile Infection has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
